Literature DB >> 12601493

Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose.

M Yasaka1, M Oomura, K Ikeno, H Naritomi, K Minematsu.   

Abstract

We investigated the effect of prothrombin complex concentrate (PCC) on the international normalized ratio (INR) and blood coagulation system in two emergent patients treated with warfarin for secondary prevention of cardioembolic stroke due to nonvalvular atrial fibrillation. An 80-year-old woman developed massive subcutaneous hemorrhage and swelling on her right upper extremity with weak pulsation of the right radial artery and had an INR above 10. An 83-year-old man had pleural effusion with an INR value of 6.69 and pleural puncture was immediately required. We administered 500 IU of PCC to the two patients (17.2 IU/kg and 12.5 IU/kg) with 10 mg of vitamin K. The INR decreased to 1.12 and 1.85, respectively, with an increase of plasma levels of protein C and coagulant factors IIa, VIIa, IXa, and Xa 10 min after administration. The plasma levels of the thrombin-antithrombin III complex increased (from 4.0 to 12.0 micro g/l and from 0.5 to 28.9 micro g/l, respectively, normal value <3.0), but prothrombin fragment 1+2 increased minimally 10 min after administration (from 0.4 to 1.1 nmol/ml and from 0.4 to 0.7 nmol/ml, respectively, normal value 0.4-1.4 nmol/ml). Plasma levels of D-dimer remained unchanged. The massive subcutaneous hemorrhage in the former patient improved in 14 days. Anticoagulation was restarted in the latter patient after 14 days of PCC administration. There were no embolic episodes during the month after PCC administration. In conclusion, a small amount of PCC may be effective in immediately correcting increased INR levels with increased plasma levels of protein C and coagulant factors IIa, VIIa, IXa, and Xa and may partially activate the coagulation system without any effects on plasma levels of D-dimer.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12601493     DOI: 10.1007/s00277-002-0568-y

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  10 in total

Review 1.  [Avoiding emergency situations under anticoagulant therapy with vitamin K antagonists].

Authors:  C E Dempfle; M Borggrefe
Journal:  Internist (Berl)       Date:  2005-09       Impact factor: 0.743

Review 2.  Management of special conditions in patients on vitamin K antagonists.

Authors:  Francesco Marongiu; Guido Finazzi; Vittorio Pengo; Daniela Poli; Sophie Testa; Armando Tripodi
Journal:  Intern Emerg Med       Date:  2011-05-27       Impact factor: 3.397

3.  Efficacy and safety of a 4-factor prothrombin complex concentrate for rapid vitamin K antagonist reversal in Japanese patients presenting with major bleeding or requiring urgent surgical or invasive procedures: a prospective, open-label, single-arm phase 3b study.

Authors:  Shigeki Kushimoto; Toshio Fukuoka; Akio Kimura; Kazunori Toyoda; Andres Brainsky; Amy Harman; Thomas Chung; Masahiro Yasaka
Journal:  Int J Hematol       Date:  2017-08-16       Impact factor: 2.490

Review 4.  Fixed-dose 4-factor prothrombin complex concentrate: we don't know where we're going if we don't know how to get there.

Authors:  Scott T Hall; Kyle C Molina
Journal:  J Thromb Thrombolysis       Date:  2018-07       Impact factor: 2.300

Review 5.  Warfarin reversal.

Authors:  J P Hanley
Journal:  J Clin Pathol       Date:  2004-11       Impact factor: 3.411

6.  Treatment of coagulopathy in intracranial hemorrhage.

Authors:  Maria I Aguilar; William D Freeman
Journal:  Curr Treat Options Neurol       Date:  2010-03       Impact factor: 3.598

Review 7.  Prothrombin complex concentrates for oral anticoagulant therapy-related intracranial hemorrhage: a review of the literature.

Authors:  Eric M Bershad; Jose I Suarez
Journal:  Neurocrit Care       Date:  2010-06       Impact factor: 3.210

8.  Spontaneous bladder rupture secondary to warfarin overdose: a case report.

Authors:  Taner Sahin; Ufuk Oner; Omer Baser; Ismail Kurtuncu
Journal:  BMC Emerg Med       Date:  2019-12-18

9.  Reversal of Vitamin K Antagonist (VKA) effect in patients with severe bleeding: a French multicenter observational study (Optiplex) assessing the use of Prothrombin Complex Concentrate (PCC) in current clinical practice.

Authors:  Thibaut Desmettre; Emilie Dehours; Charles-Marc Samama; Suchin Jhundoo; Frédéric Pujeau; Christian Guillaudin; Claudine Hecquart; Pierre Clerson; Jean Charles Crave; Roland Jaussaud
Journal:  Crit Care       Date:  2012-10-04       Impact factor: 9.097

10.  Prothrombin complex concentrate (Beriplex P/N) in severe bleeding: experience in a large tertiary hospital.

Authors:  David Bruce; Tim J C Nokes
Journal:  Crit Care       Date:  2008-08-15       Impact factor: 9.097

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.